Sedegah M, Charoenvit Y, Minh L, Belmonte M, Majam VF, Abot S, Ganeshan H, Kumar S, Bacon DJ, Stowers A, Narum DL, Carucci DJ, Rogers WO. 2004. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Therapy 11(5):448–456.

Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ. 1994. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: Involvement of interferon gamma and CD8+ T cells. Journal of Experimental Medicine 180(1):353–358.

Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JD Jr, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC. 1996. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 14(8):817–827.

Snow RW, Korenromp EL, Gouws E. 2004. Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? American Journal of Tropical Medicine and Hygiene 71(suppl 2):16–24.

Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030):214–217.

Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. New England Journal of Medicine 336(2):86–91.

Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CE, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR. 1998. Long-term efficacy and immune response following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 178(4):1139–1144.

Struck MM. 1996. Vaccine R&D success rates and development times. Nature Biotechnology 14(5):591–593.

Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Menard R. 1997. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell 90(3):511–522.

Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U. 2003. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. Journal of Immunology 171(12):6961–6967.

Targett GA. 2005. Malaria vaccines 1985-2005: A full circle? Trends in Parasitology 21(11):499–503.

Thomas AW, Carr DA, Carter JM, Lyon JA. 1990. Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Molecular and Biochemical Parasitology 43(2):211–220.

Top FH Jr., Dingerdissen JJ, Habig WH, Quinnan GV Jr., Wells RL. 2000. DoD Acquisition of Vaccine Production. Report to the Secretary of Defense by the Independent Panel of Experts, Dec 2000. In DoD, 2001. Report on Biological Warfare Defense Vaccine Research and Development Programs. Washington D.C.: Department of Defense. [Online]. Available: http://www.acq.osd.mil/cp/bwdvrdp-july01.pdf [Accessed May 3 2006].

Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon JA, Holder AA. 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. Journal of Molecular Biology 307(5):1381–1394.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement